Shots:

• The P-II BLAZE-4 study involves assessing bamlanivimab as monothx. and bamlanivimab (700mg) + VIR-7831 (500mg) vs PBO in 1000 participants with symptomatic low-risk COVID-19 in the outpatient setting across the US and Puerto Rico
• Results: The dual regimen met its 1EPs i.e. 70% relative reduction in persistently high viral load (> 5.27; cycle threshold value < 27.5) @day7. Additionally- it showed a reduction in the key virologic 2EPs of mean change from baseline to days 3- 5 and 7 in SARS-CoV-2 viral load
• The preclinical data suggested that the administration of Bamlanivimab + VIR-7831 together may provide protection against current variants of SARS-CoV-2 that are resistant to bamlanivimab

  Ref: GSK | Image: GSK